Rebus Holdings, Inc.
2629 Townsgate Road
Suite 215
Westlake Village, CA 91361
United States
818 597 7552
https://www.rebus-corp.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Raul Silvestre Esq. | CEO, CFO, President, Principal Accounting Officer & Director | 無 | 無 | 1971 |
| Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor | 無 | 無 | 無 |
| Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board | 無 | 無 | 無 |
截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
公司管治
截至 無 止，Rebus Holdings, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
